InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,574.40
(
-0.20%
)
Dow Jones
38,852.27
(
0.00%
)
Brent Oil
83.02
(
-0.55%
)
Bitcoin
63,509.32
(
0.56%
)
Post# of 251732
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 828
Posts 119581
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 178534

Friday, 03/13/2015 7:35:43 PM

Friday, March 13, 2015 7:35:43 PM

Post# of 251732
Aduro files for IPO:

http://www.bizjournals.com/sanfrancisco/blog/biotech/2015/03/berkeleycancer-therapy-startup-aduro-biotech-seeks.html

Led by CEO Stephen T. Isaacs, Aduro was founded in 2000 to develop early-stage cancer therapies. Isaacs will have a 3.3 percent interest with the IPO. The company currently has a drug in a Phase IIb study for pancreatic cancer.

…The Berkeley-based biotech firm has raised $143.4 million to date in eight rounds from investors, such as Morningside Group, Johnson & Johnson, OrbiMed and Janus Capital Group. Aduro plans to list on the Nasdaq under the symbol ADRO.

ADXS is considered a close competitor.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up